Moleculin Biotech (MBRX) Prices 14.27M Share Common Offering at $4.75/Sh

Moleculin Biotech, Inc., (NASDAQ: MBRX) today announced the pricing of an underwritten public offering of an aggregate of 14,273,684 shares of common stock at a public offering price of $4.75 per share. Moleculin has granted the underwriters a 30-day option to purchase up to an additional 2,141,052 shares of common stock offered in the public offering. The offering is expected to close on or about February 5, 2021, subject to customary closing conditions.

The gross proceeds of the offering are expected to be $67.8 million, prior to deducting the underwriting discount and other estimated offering expenses but excluding any exercise of the underwriters' option. The Company intends to use the net proceeds of the offering to fund its planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes.

Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering and Roth Capital Partners, LLC is acting as the co-manager for the offering. Maxim Group LLC is acting as financial advisor to the Company.

You May Also Be Interested In

• Wrap Technologies prices $12M direct offering at $1.40 per share
• OLB Group narrows net loss 50% as revenue falls in Q2 2026
• Aptevo Therapeutics raises $4.5M through warrant exercise and PIPE